Booth L, West C, Von Hoff D, Kirkwood J, Dent P. GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells. Front Oncol. 2021;11:656453 pubmed publisher

Li S, Song Y, Quach C, Guo H, Jang G, Maazi H, et al. Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat Commun. 2019;10:1693 pubmed publisher

Rajala A, Wang Y, Rajala R. Constitutive Activation Mutant mTOR Promote Cone Survival in Retinitis Pigmentosa Mice. Adv Exp Med Biol. 2018;1074:491-497 pubmed publisher

Okada K, Nogami A, Ishida S, Akiyama H, Chen C, Umezawa Y, et al. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway. Oncotarget. 2018;9:8870-8886 pubmed publisher

Palmieri M, Pal R, Nelvagal H, Lotfi P, Stinnett G, Seymour M, et al. mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. Nat Commun. 2017;8:14338 pubmed publisher

Urano J, Sato T, Matsuo T, Otsubo Y, Yamamoto M, Tamanoi F. Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc Natl Acad Sci U S A. 2007;104:3514-9 pubmed